This document provides information about the 7th Annual Mild Cognitive Impairment Symposium that will take place on March 27-28, 2009 in Miami, Florida. The symposium will focus on early Alzheimer's disease and non-Alzheimer's prodromal dementias. It will feature keynote speakers and breakout sessions on topics such as vascular cognitive impairment, prevention and treatment of mild cognitive impairment and early Alzheimer's, and distinguishing between early Lewy body disease and Alzheimer's disease. The document provides details on registration, continuing education credits, the agenda, faculty members, and objectives of the symposium.
The goal of this webinar was to educate physicians and healthcare professionals about hospice eligibility and the benefits of hospice for patients with advanced cardiac disease (ACD).
Advanced Lung Disease: Prognostication and Role of HospiceVITAS Healthcare
The goal of this webinar was to educate physicians and healthcare professionals about the medical management of advanced lung disease (ALD), the value of advance care planning (ACP), and the benefits of hospice for end-of-life patients.
Deciding When Hospice Care is Needed | VITAS HealthcareVITAS Healthcare
The goal of this webinar is to help healthcare professionals address the specific challenges of end-of-life care when determining a terminal prognosis, so they can provide the optimum care for the patient and family during the final stages of life.
The goal of this webinar was to help hospice and healthcare professionals understand the ethics and application of artificial nutrition and hydration (ANH) for patients near the end of life.
Evaluation and Management of Behaviors in Persons with Cognitive ImpairmentVITAS Healthcare
The goal of this webinar is to enable healthcare clinicians to implement a comprehensive approach to non-pharmacologic and pharmacologic management of dementia-related behaviors for the benefit of patients and their caregivers.
Respiratory Symptoms in the Terminally Ill PatientVITAS Healthcare
The goal of this webinar was to educate healthcare professionals on interventions for cough, dyspnea, hemoptysis, and the “death rattle” in patients with end-of-life respiratory symptoms.
This webinar provides expert guidance and clear answers to common myths about hospice care. Learn about the history and philosophy of hospice care, common hospice prognoses, who pays for hospice, and the difference between hospice and palliative care. Explore the four levels of care and the role of the interdisciplinary hospice team to provide medical, psychosocial and spiritual solutions that support quality of life at the end of life for patients and families. Learn how advance directives can ensure patients are referred to hospice care early in the disease process to enjoy its full benefits.
A Change in Behavior: A Pragmatic Clinical Guide to Delirium, Terminal Restle...VITAS Healthcare
The goal of this webinar was to help physicians and healthcare professionals differentiate delirium, terminal restlessness, and dementia-related agitation and aggression in patients near the end of life.
Chronic Obstructive Pulmonary Disease (COPD) is the third-leading cause of death in America, yet less than 9 percent of those patients near the end of life are admitted to hospice. These slides looks at the effects of COPD and other Advanced Lung Diseases (ALD) and how palliative care and hospice can improve patient care and clinical outcomes.
NOTICE:
This Webinar was intended to provide general educational information only. The information presented should not be viewed as specific medical advice regarding a particular patient. It is always a medical provider’s responsibility to individually assess and evaluate each patient before providing that patient medical advice or initiating any medical intervention.
The goal of this webinar was to educate physicians and healthcare professionals about hospice eligibility and the benefits of hospice for patients with advanced cardiac disease (ACD).
Advanced Lung Disease: Prognostication and Role of HospiceVITAS Healthcare
The goal of this webinar was to educate physicians and healthcare professionals about the medical management of advanced lung disease (ALD), the value of advance care planning (ACP), and the benefits of hospice for end-of-life patients.
Deciding When Hospice Care is Needed | VITAS HealthcareVITAS Healthcare
The goal of this webinar is to help healthcare professionals address the specific challenges of end-of-life care when determining a terminal prognosis, so they can provide the optimum care for the patient and family during the final stages of life.
The goal of this webinar was to help hospice and healthcare professionals understand the ethics and application of artificial nutrition and hydration (ANH) for patients near the end of life.
Evaluation and Management of Behaviors in Persons with Cognitive ImpairmentVITAS Healthcare
The goal of this webinar is to enable healthcare clinicians to implement a comprehensive approach to non-pharmacologic and pharmacologic management of dementia-related behaviors for the benefit of patients and their caregivers.
Respiratory Symptoms in the Terminally Ill PatientVITAS Healthcare
The goal of this webinar was to educate healthcare professionals on interventions for cough, dyspnea, hemoptysis, and the “death rattle” in patients with end-of-life respiratory symptoms.
This webinar provides expert guidance and clear answers to common myths about hospice care. Learn about the history and philosophy of hospice care, common hospice prognoses, who pays for hospice, and the difference between hospice and palliative care. Explore the four levels of care and the role of the interdisciplinary hospice team to provide medical, psychosocial and spiritual solutions that support quality of life at the end of life for patients and families. Learn how advance directives can ensure patients are referred to hospice care early in the disease process to enjoy its full benefits.
A Change in Behavior: A Pragmatic Clinical Guide to Delirium, Terminal Restle...VITAS Healthcare
The goal of this webinar was to help physicians and healthcare professionals differentiate delirium, terminal restlessness, and dementia-related agitation and aggression in patients near the end of life.
Chronic Obstructive Pulmonary Disease (COPD) is the third-leading cause of death in America, yet less than 9 percent of those patients near the end of life are admitted to hospice. These slides looks at the effects of COPD and other Advanced Lung Diseases (ALD) and how palliative care and hospice can improve patient care and clinical outcomes.
NOTICE:
This Webinar was intended to provide general educational information only. The information presented should not be viewed as specific medical advice regarding a particular patient. It is always a medical provider’s responsibility to individually assess and evaluate each patient before providing that patient medical advice or initiating any medical intervention.
Discussion post reply APA Format2 references for each discussiLyndonPelletier761
Discussion post reply
APA Format
2 references for each discussion post with intext citation.
Make it short and simple.
Post # one
Misty B
I have chosen to become a Psychiatric Mental Health Nurse Practitioner. I chose this path because I feel God is calling me to help guide and mentor people through this age of transition. With the increase of the digital age, social media specifically, and the COVID Pandemic, peoples’ mental health needs need to be cared for in a better manner than how they are currently being managed. “The role of the PMHNP is to assess, diagnose and treat the mental health needs of patients. Many PMHNPs provide therapy and prescribe medication for patients who have mental health disorders or substance abuse problems.” (American Association of Nurse Practitioners, n.d.) I believe your overall health begins with a healthy mind. When your mental health is not healthy you can spiral out of control and turn to substances (illicit drugs, alcohol, food, etc.) or self-harm. This can lead to other health problems such as obesity, diabetes, cardiovascular disorders, liver disorders, kidney disorders, etc. I feel as a PMHNP I will be able to start with the root cause of a patient’s overall health. I waxed and waned with my decision between a PMHNP and FNP. I feel starting with PMHNP is the best option for me at the moment and continuing afterward to have a dual certification as an FNP.
Professional Organization
“Another factor essential to a nurse’s professional development is active membership in 1 or more professional organization. Memberships provide exposure and access to education resources (eg, websites, webinars, publications, and conferences) and rewarding networking opportunities with peers and colleagues.” (Cherry et all, 2019)
Having been a member of the Emergency Nurses Association (ENA) for 8 years, I too feel it is important to become a member of your of an association for your nursing specialty. I have chosen to become a member of the American Psychiatric Nurses Association. Their mission statement and beliefs are parallel to my own.
APNA is committed to the practice of psychiatric-mental health nursing, health and wellness promotion through identification of mental health issues, prevention of mental health problems, and the care and treatment of persons with mental health disorders. APNA champions psychiatric-mental health nursing and mental health care through the development of positions on key issues, the dissemination of current knowledge and developments in PMH nursing, and collaboration with stakeholders to promote advances in recovery-focused assessment, diagnosis, treatment, and evaluation of persons with mental health disorders. (American Psychiatric Nurses Association, n.d.)
Becoming a member was as easy as going to their website www.apna.org and selecting your membership type, fill in the required information, and pay the fee. Being a member will give me access to educational oppo ...
Mayo Clinic - 2011 ACC Satellite Education Symposiumswest0521
This is satellite educational symposium during the 2011 ACC Scientific Session. The program would be of interest for imaging professionals, cardiologists, radiologists, nuclear cardiology and nuclear medicine specialists and other healthcare providers interested in the application of cardiac imaging in clinical practice.
Problems and perspectives of development of psycho-oncology in Georgia and in...Nata Chalanskaya
Ekaterine Sanikidze, Director at Tbilisi Cancer Center, Georgian Patients’ Union Adviser, presentation at the Second International Scientific and Practical Conference «Improving the quality of life of cancer patients through the development of cooperation between state, commercial and non-profit organizations». 2018-01-24, Minsk. Belarus.
Blazing New Trails: Shifting the Focus on Alcohol and Drugsnashp
Presented at the National Academy for State Health Policy's 20th Annual State Health Policy Conference in Denver, Colorado. Authors: Barbara Cimaglio, Sally Fogerty, BSN, M.Ed., John C. Higgins-Biddle, Ph.D.
Great Expectations for Great Applications 2009Emil Chuck
Presentation from September 3, 2009, prehealth convocation to advisees. Includes survey data from 2009-2010 Welcome Week Survey, AAMC admissions directors survey 2009, and competency-based evaluations including ETS PPI. (Sorry, the audio is a bit fuzzy: recorder was in my shirt pocket as I was moving around.)
Abstract—Prevalence of degenerative dementias and dementias associated with cerebrovascular disease is increasing with the time. Dementia is one of the most significant public health problems. Demographic data, medical history, general biochemical data and serum total homocysteine (tHcy) levels was used in this study to examine the differences between dementia and normal control groups. A cross-sectional study was conducted on 236 individuals who were above the age of 65 years. These participants went through the Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR), demographic characteristics, biochemical data and tHcy level. Each of the above mentioned factors was assessed. There were significant differences in the history of hypertension, diabetes mellitus, marital status, alcohol consumption (AC), BMI value, and triglyceride (TG) and serum tHcy levels. The logistic regression analysis showed significant differences in marital status, AC and tHcy. So it can be concluded that elevated serum tHcy, no AC and no partner are associated with the risk of dementia in elders of Southern Taiwan. It needs further researches to identify and reduce the risk of dementia.
NIMH i PSC Assays for the Drug Pipeline - Panchisionwef
Dr David Panchision's live presentation at the Schizophrenia Research Forum's live webinar of June 28, 2017 - http://www.schizophreniaforum.org/forums/webinar-modeling-neuropsychiatric-disorders-using-vitro-models
Schizophrenia Research Forum Live Webinar - June 28, 2017 - Rusty Gage wef
Fred Gage's live presentation at the Schizophrenia Research Forum's live webinar of June 28, 2017 - http://www.schizophreniaforum.org/forums/webinar-modeling-neuropsychiatric-disorders-using-vitro-models
SCHIZOPHRENIA RESEARCH FORUM - LIVE WEBINAR June 2017 Kristen Brennandwef
Kristen Brennand presentation at the live webinar of June 28, 2017 hosted by the Schizophrenia Research Forum (http://www.schizophreniaforum.org/forums/webinar-modeling-neuropsychiatric-disorders-using-vitro-models)
STRATEGIES FOR COMMUNICATION AND SENSITIVITY FOR PERSONS EXPERIENCING DEMENTI...wef
Live presentation recorded June 21, 2017, featuring Ellen Phipps and Devin Bowers - review additional material at www.alzpossible.org/strategies-for-communication/
Translating from Animal Models to Human Schizophrenia - Insights into Pathoph...wef
Presentation made by Dr. Tony Grace at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
Presentation made by Dr. Oliver Howes at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
Topography and functional significance of the dopaminesgic dysfunction in sch...wef
Presentation made by Dr. Anissa Abi-Dargham at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
SRF Webinar - What It Will Take to Make Coordinated Specialty Care Available ...wef
Presentation made March 22, 2017, during the live webinar hosted by Schizophrenia Research Forum (SRF). Event recording and additional slides at http://www.schizophreniaforum.org/forums/achieving-effective-treatment-early-psychosis-united-states
SRF Webinar: Beyond DUP - Addressing Disengagement in Community-based Early I...wef
Presentation made March 22, 2017, during the live webinar hosted by Schizophrenia Research Forum (SRF). Event recording and additional slides at http://www.schizophreniaforum.org/forums/achieving-effective-treatment-early-psychosis-united-states
Presentation made March 17, 2017 and hosted by AlzPossible - www.alzpossible.org.
Review recording at http://alzpossible.org/webinars-2/the-basics-memory-loss-dementia-and-alzheimers-disease/
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
Oliver Howes - Treatment-Resistant Schizophrenia: New Guidelines on Diagnosis...wef
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
John Kane - Treatment-Resistant Schizophrenia: New Guidelines on Diagnosis an...wef
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
HEAR approach to behavior management Live webinar Feb 1 2017wef
Slides presented at the HEAR Approach to Behavior Management live webinar of February 1, 2017, featuring presentations from Dr. Andrew Heck and Carol Garby.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
1. 7TH
ANNUAL
March
27th & 28th
2009
Save the Date!
Accreditation
Mount Sinai Medical Center is
accredited by the Accreditation
Council for Continuing Medical
Education (ACCME) to sponsor
continuing medical education for
physicians. Mount Sinai
designates this educational
activity for a maximum of 15.5
AMA PRA Category 1 Credits™.
Physicians should only claim
credit commensurate with the
extent of their participation in
the activity.
Psychology Credit
The MCI Symposium has been
approved by the Florida Board
of Psychology and the Miami
Area Geriatric Education Center
(MAGEC). This program has
been approved for 15 contact
hours. (MAGEC CE Broker
Tracking #20-213847).
Disclosure Statement
Faculty relationship(s) with industry will be disclosed and available in the
Symposium Syllabus and at the meeting site. Disclosure to the audience will be
made by the Faculty prior to their presentations by the Activity Director.
As a provider accredited by the Accreditation Council for Continuing Medical
Education, Mount Sinai Medical Center requires its staff, and CME Committee
members (i.e. Planners) to disclose to all stakeholders and learners that the
individual either has or does not have Relevant Financial Relationship(s) with a
commercial interest. Therefore, anyone in a position to control CME content must
complete a Disclosure of Financial Relationship form. Planner relationship(s) with
industry will be disclosed and available in the Symposium Syllabus.
Corporate Support
This symposium is made possible by unrestricted educational grants from
pharmaceutical companies; our appreciation is expressed for their support of
this program. Sponsors will be listed in our Symposium Syllabus and on the
Symposium Web-Site.
Acknowledgment
This symposium is being supported by the Florida Alzheimer’s Disease Research
Center (ADRC).
Symposium Information
Please contact one of the following:
Wien Center
4300 Alton Road
Miami Beach, FL 33140
Presented By:
The Wien Center for Alzheimer’s Disease and Memory Disorders
Mount Sinai Medical Center, Miami Beach, Florida
and
The Johnnie B. Byrd, Sr. Alzheimer’s Center & Research Institute
University of South Florida, Tampa, Florida
FRIDAY – SATURDAY / March 27 - 28, 2009
Symposium Location:
Intercontinental Hotel
100 Chopin Plaza
Miami, FL 33131
Program Director:
Ranjan Duara, MD
Medical Director, Wien Center for Alzheimer’s Disease and Memory Disorders
Mount Sinai Medical Center, Miami Beach
Departments of Medicine, Neurology and Psychiatry
Miller School of Medicine, University of Miami, Miami, FL
Department of Neurology, University of South Florida College of Medicine, Tampa, FL
Sponsored By:
The Behrman Center for Medical Education
at Mount Sinai Medical center
7TH
ANNUAL
MARK YOUR CALENDAR
MILD COGNITIVE IMPAIRMENT (MCI) SYMPOSIUM
Theme for 2009: Focus on Early Alzheimer's Disease & Non-Alzheimer's Prodromal Dementias
www.mcisymposium.org
Warren Barker
Wien Center for Alzheimer’s Disease
& Memory Disorders
Mount Sinai Medical Center
Phone: 305-674-2592 Fax: 305-674-2259
Yirah Ochoa
Wien Center for Alzheimer’s Disease
& Memory Disorders
Mount Sinai Medical Center
Phone: 305-674-2018
E-mail: info@mcisymposium.org
Web: www.mcisymposium.org
2. Distinguished Faculty
Program Director
Ranjan Duara, MD
Medical Director, Wien Center for Alzheimer’s Disease and Memory Disorders
Mount Sinai Medical Center, Miami Beach
Departments of Medicine, Neurology and Psychiatry
Miller School of Medicine, University of Miami, Miami, FL
Department of Neurology, University of South Florida College of Medicine, Tampa, FL
Needs Assessment
Unless ways are found to prevent
Alzheimer’s Disease (AD) or delay its onset,
it is projected that over 13 million people in
the United States will be living with AD by
2050. Individuals with AD suffer from
cognitive and functional impairment, loss of
productivity and significant deterioration in
over-all quality of life. Most will develop
problematic behaviors and many will need
long-term care. In addition, caregivers of
the patients are adversely affected by the
physical burden, emotional distress and
financial hardship.
Since the development of criteria for AD
almost twenty-five years ago, there have
been major advances in our understanding
of the biology and clinical features of several
causes of dementia, including AD. Success
in the development of treatments has
prompted the need for a better recognition of
the early stages of dementia, and the need
to differentiate AD from other disorders, such
as Lewy Body Disease and vascular
cognitive impairment. Advances in clinical
neuropsychological assessment, brain
imaging and biological markers have
improved our ability to detect the disease
earlier and monitor its progression with
regards to treatment. Further, current
practice guidelines from the American
Academy of Neurology include a
recommendation for the “evaluation and
clinical monitoring of persons with mild
cognitive impairment due to their increased
risk for developing dementia”. Several
studies have shown that physicians often lack
knowledge of the early signs and symptoms
of AD, which leads to delays in
pharmacological treatment and other
interventions (e.g., caregiver education,
legal and financial counseling).
Target Audience
This activity is designed for:
- Neurologists
- Psychiatrists
- Geriatricians / Gerontologists
- Epidemiologists
- Neuropsychologists
- Psychologists
- Neuroscientists
Educational Objectives
The purpose of this symposium is to provide a
forum for new information and for in-depth
discussions about advances in research, related to
the clinical diagnosis, progression and treatment of
Alzheimer’s Disease and other causes of dementia.
This symposium will emphasize the early stage of
cognitive syndromes, such as mild cognitive
impairment, that are associated with increased risk
for developing dementia. We will examine recent
developments in understanding risk factors which
lay the groundwork for potential strategies for
treating and delaying Alzheimer’s disease. We will
also study differences at the biological and clinical
level between the three most common causes of
dementia – AD, Lewy Body Disease and Vascular
Cognitive Impairment. Finally, we will present
results from several studies on pharmacological
and non-pharmacological interventions for
Alzheimer’s Disease and cognitive impairment with
a primarily vascular etiology.
The symposium will include two keynote addresses,
a panel discussion, and four individually themed
symposia, each featuring national and
international experts in the fields of neurology,
neurobiology, psychiatry, geriatrics,
neuropsychology, radiology, epidemiology and
pharmacology. Each mini-symposium will be
followed by an extended discussion period,
allowing active audience participation to promote
a better understanding of the issues.
Keynote Speakers:
Ronald Petersen, MD, PhD
Professor of Neurology and Alzheimer’s
Disease Research
Mayo Medical School
Rochester, Minnesota
Vladimir Hachinski, MD, ScD
Professor, Neurology & Epidemiology
University of Western Ontario
London, Ontario, Canada
Faculty:
Liana Apostolova, MD
Assistant Director, Structural Imaging
Los Angeles Alzheimer’s Disease Center
University of California
Los Angeles, California
Randall Bateman, MD
Assistant Professor of Neurology
Washington University School of Medicine
St. Louis, Missouri
David A. Bennett, MD
Robert C. Borwell Professor of
Neurological Sciences
Director, Rush Alzheimer’s Disease Center
Rush University Medical Center
Chicago, Illinois
Deborah Blacker, MD, ScD
Director, Gerontology Research
Associate Professor of Psychiatry
Mass General Hospital
/Harvard Medical School
Boston, Massachusetts
Bradley F. Boeve, MD
Professor of Neurology
Mayo Clinic
Rochester, Minnesota
Amy Borenstein, PhD
Professor of Epidemiology and Biostatistics
College of Public Health
University of South Florida
Tampa, Florida
Brian Carpenter, PhD
Associate Professor, Department of
Psychology
Washington University
St. Louis, Missouri
Steven DeKosky, MD
James Carroll Flippin Professor
of Medical Science
Vice President and Dean
University of Virginia School of Medicine
Charlottesville, Virginia
Timo Erkinjuntti, MD, PhD
Professor of Neurology
Head of the University Department of
Neurological Sciences, University of Helsinki
Head physician, Department of Neurology
and Memory Research Unit
Helsinki University Central Hospital, Finland
Mary Ganguli, MD, MPH
Professor of Psychiatry and Epidemiology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Douglas R. Galasko, MD
Professor, Department of Neurosciences
Neurology Service, San Diego VAMC
University of California,
San Diego, California
William Haley, PhD
Professor, School of Aging
University of South Florida
Tampa, Florida
Frank LaFerla, PhD
Professor, Neurobiology & Behavior
University of California
Irvine, California
Nicola T. Lautenschlager, MD, FRANZCP
Professor & Chair of Psychiatry of Old Age
Head of the Academic Unit,
Psychiatry of Old Age
University of Melbourne Dept. of Psychiatry
Melbourne, Victoria, Australia
Oscar Lopez, MD
Professor of Neurology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Katie Palmer, PhD
Marie Curie EU Fellow
Santa Lucia Foundation IRCCS
Rome, Italy, Sweden
Joseph Parisi, MD
Professor of Laboratory Medicine and
Pathology
Mayo Clinic
Rochester, Minnesota
Owen A. Ross, PhD
Assistant Professor of Neuroscience
Mayo Clinic College of Medicine
Jacksonville, Florida
Steve Salloway, MD, MS
Professor of Clinical Neurosciences and
Psychiatry
Brown Medical School
Providence, Rhode Island
Julie Schneider, MD
Associate Professor of Neurology and
Neuropathology
Rush University Medical Center
Chicago, Illinois
Lon Schneider, MD
Professor of Psychiatry
University of Southern California
Keck School of Medicine
Los Angeles, California
Sudha Seshadri, MD
Associate Professor & Co-Director of Medical
Education for Residency Program
Department of Neurology,
Boston University School of Medicine
Investigator, The Framingham Heart Study
Boston, Massachusettes
Ingmar Skoog, MD, PhD
Professor in Psychiatry
Institute of Neuroscience and Physiology,
Unit of Neuropsychiatric Epidemiology
Sahlgrenska Academy at University of
Gothenburg
Gothenburg, Sweden
Alexander I. Tröster, PhD
Professor, Department of Neurology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Sandra Weintraub, PhD
Professor, Division of Psychology
Neurology and Alzheimer’s Disease Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Jennifer Whitwell, PhD
Aging and Dementia Imaging Laboratory
Mayo Clinic
Rochester, Minnesota
3. AM
7:30-8:30 Breakfast Buffet
8:30-9:15 Keynote Address: Prevention of
Dementing Disorders
Vladimir Hachinski, MD
9:15-11:30 Mini-Symposium: Vascular Cognitive
Impairment (VCI) – Pathological
Mechanisms, Genetics, Epidemiology
and Clinical Features
Chair: David Bennett, MD
Vascular Risk Factors for MCI in the
Cardiovascular Health Study
Oscar Lopez, MD
Genetic Risk Factors for Cerebrovascular
Disease
Sudha Seshadri, MD
Contribution of Vascular Lesions to MCI
Julie Schneider, MD
Biology of VCI, CADASIL and Association
with Amyloid/Taupathology
Steve Salloway, MD
Neuroimaging of Vascular Cognitive
Impairment
Timo Erkinjuntti, MD, PhD
11:30-11:45 Break
11:45-12:30 Open Discussion
12:30-1:45 LUNCH BREAK
PM
1:45-4:00 Mini-Symposium: Prevention and
Treatment of MCI and Very Early AD
Chair: Lon Schneider, MD
Recent Phase II and III Clinical Trials
of Disease Modifying Preventive Agents
for AD
Lon Schneider, MD
The Ginkgo Evaluation of Memory Study
Steven DeKosky, MD
Tau as a Target for Treatment of MCI
and AD
Frank LaFerla, PhD
Effect of Physical Activity on Cognitive
Function in the Elderly: A Clinical Trial
Nicola Lautenschlager, MD
Clinical Trials of Anti-Hypertensive
Medication for MCI
Ingmar Skoog, MD, PhD
4:00-4:15 Break
4:15-5:00 Open Discussion
5:00 Adjourn
Saturday, March 28, 2009
PM
1:45-4:00 Mini-Symposium: Early LBD versus Early AD
- Pathological Mechanisms, Genetics,
Epidemiology and Clinical Features
Chair: Douglas Galasko, MD, PhD
Biology of Alphasynucleinopathies and
Association of Amyloid/Tau Pathology
Joseph Parisi, MD
Comparative Genetics of Parkinson’s, Lewy
Body Disease and AD
Owen Ross, PhD
REM Sleep Behavior Disorder and Clinical
Features of MCI-LBD
Brad Boeve, MD
Differentiation of the Neuropsychological
Features of MCI-LBD from other MCIs
Alexander Tröster, PhD
4:00-4:15 Break
4:15-5:00 Open Discussion
5:30-7:00 Panel Discussion: Disclosing the Diagnosis
of MCI Chair: Randall Bateman, MD
Panelists: Deborah Blacker, MD, ScD; Brian
Carpenter, PhD; William Haley, PhD
7:00-9:30 WELCOME DINNER
Friday, March 27, 2009
AM
7:00-8:00 Breakfast Buffet
8:00-8:15 Welcome and Introduction
Ranjan Duara MD
8:15-9:15 Keynote Address: MCI: 10 Years Later
Ronald Petersen, MD,PhD
9:15-11:30 Mini-Symposium: Epidemiology and
Clinical Features of Amnestic and
Non-Amnestic MCI Syndromes
Chair: Mary Ganguli, MD, MPH
Incidence and Prevalence of Amnestic
and Non-Amnestic MCI Syndromes
and Rates of Progression to AD
& Dementia
Katie Palmer, PhD
Factors Mediating the Transition
Rates of Amnestic and Non-Amnestic
MCI Syndromes
Amy Borenstein, PhD
Assessment of Functional Status
in Amnestic and Non-Amnestic
MCI syndromes
Sandra Weintraub, PhD
Neuropsychiatric Associations of
Amnestic and Non-Amnestic
MCI Syndromes
Liana Apostolova, MD
Neuroimaging in Amnestic and Non-
Amnestic MCI Syndromes
Jennifer Whitwell, PhD
11:30-11:45 Break
11:45-12:30 Open Discussion
12:30-1:45 LUNCH BREAK
Scientific Agenda
4. MILD COGNITIVE IMPAIRMENT (MCI) SYMPOSIUM
Registration Form
THREE EASY WAYS TO REGISTER
ONLINE: FAX: MAIL:
www.mcisymposium.org Attn: Warren Barker Warren Barker
(305) 674-2259 Mount Sinai
4300 Alton Road
Miami Beach, FL 33140
REGISTRANT INFORMATION Please print:
_________________________________________________________________________________________
LAST NAME FIRST NAME MIDDLE NAME
DEGREE: MD DO PhD OTHER
_________________________________________________________________________________________
INSTITUTION / ORGANIZATION
__________________________________________________________________________________________________________________________________
STREET ADDRESS
________________________________________________________________________________________________________________________________
CITY STATE ZIP CODE COUNTRY
________________________________________________________________________________________________________________________________
E-MAIL TELEPHONE
REGISTRATION FEES:
Physicians: $340.00 (if dated/postmarked by February 28)
$390.00 (if dated/postmarked after February 28)
$440.00 (on site registration)
Non-Physicians: $225.00 (if dated/postmarked by February 28)
$275.00 (if dated/postmarked after February 28)
$325.00 (on site registration)
$100.00 (students)
PAYMENT METHOD:
American Express Master Card Visa Check in the amount of _____________
Card No. _______________________________________________ Expiration Date _____/_____
Cardholder’s Name _________________________________________________________________
Signature __________________________________________________________________________
________________________________________________________________________________________________________________________________
NAME & ADDRESS ON CARD IF DIFFERENT THAN ABOVE
________________________________________________________________________________________________________________________________
Payment must accompany registration form. Refund Policy: Full refund will be given if written notice
is received not later than February 28, 2009. All refunds will be processed after the meeting.
Method of Registration
To register by mail or fax: please
complete the registration form and send it
with the payment to the above mailing
address or fax number.
To register by internet:
www.mcisymposium.org
Registration confirmations will be issued.
Payment: Registration fees can be paid by
credit card or check, no cash is accepted.
Please make all checks payable to:
MOUNT SINAI MEDICAL CENTER
Registration Fee Inclusions: Registration
fees include admittance to all the scientific
conferences, conference materials,
validated parking, breakfast, lunch,
refreshment breaks and welcome dinner as
specified in the program.
Registration Hours: The conference
registration desk will be staffed:
Thursday, March 26
Bayfront Foyer
4:00 pm – 7:00 pm
Friday, March 27
Meeting Room: Bayfront Ballroom
7:00 am - 5:00 pm
Saturday, March 28
Meeting Room: Bayfront Ballroom
7:00 am - 5:00 pm
Registration Information
Symposium Location
InterContinental Hotel Miami:
100 Chopin Plaza, Miami, FL 33131
Phone: 1- 866-577-3753
Web-Site: http://www.icmiamihotel.com
Miami is truly one of the world's most vibrant
tropical playgrounds. In this stunning locale, a
pulsing nightlife, brilliant white-sand beaches,
and sizzling culture combine for the perfect
getaway. At the InterContinental Miami you will
savor the best of this
colorful city. This alluring
downtown Miami hotel
offers richly appointed
accommodations and
breathtaking views of
Biscayne Bay. Immerse yourself in luxurious
elegance - just minutes from South Beach, the
Port of Miami, Coconut Grove, and Coral Gables.
Boasting 641 newly redecorated guest rooms and
suites, we're an oasis of sophistication and world-class
service. Discover this enchanting downtown Miami
Florida hotel, in a magical setting.
DRESS
Business casual attire is appropriate for all events. A light sweater or jacket
is recommended in the meeting rooms.
Hotel Reservations
For the convenience of the 7th Annual MCI Symposium attendees, a limited
number of rooms have been reserved at the special daily rate of $269.00
(single or double occupancy, plus resort fees, state and local taxes). To
receive this conference rate, reservations must be made directly with the
Intercontinental Hotel and you must mention that you are a registrant of the
7th Annual MCI Symposium. Rooms will be held at the special rate until
Tuesday, March 3, 2009. Rooms at the discounted rate will be allocated on
a first-come, first-served basis. Reservations received after the cut-off date
are subject to availability and prevailing rates.
FOR ROOM RESERVATIONS CALL: 1-866-577-3753
OR ACCESS THE HOTEL WEB SITE VIA: http://www.icmiamihotel.com
7TH
ANNUAL
MARK YOUR CALENDAR